The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.h

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Publications

Carson LN, Pradhan A, Subramanian D

Omalizumab-associated eosinophilic granulomatosis with polyangiitis: cause or coincidence?

BMJ case reports. 2021;14(7)

Dunogué B, Pagnoux C, Guillevin L

Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment.

Seminars in respiratory and critical care medicine. 2011;32(3):298-309

Szwarc D, Veillon F, Moser T, Averous G, De Blay F, Riehm S

[Churg-Strauss syndrome under omalizumab treatment: a rare visceral manifestation].

Journal de radiologie. 2009;90(11 Pt 1):1737-9

Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L

Churg-strauss syndrome in patients treated with omalizumab.

Chest. 2009;136(2):507-518

Ruppert AM, Averous G, Stanciu D, Deroide N, Riehm S, Poindron V, Pauli G, Debry C, de Blay F

Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment.

The Journal of allergy and clinical immunology. 2008;121(1):253-4